Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- MET-4 in Advanced Head and Neck Squamous Cell Carcinoma
NCT05743777Phase 2Withdrawn
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Live Biotherapeutic Products
01
Overview
A Phase 2 trial of MET-4 in head and neck squamous cell carcinoma (HNSCC), sponsored by Canadian Cancer Trials Group. Planned start May 2023; status: withdrawn.
02
Drugs
MET-4
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05743777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743777.